[HTML][HTML] Enteric coating of tablets containing an amorphous solid dispersion of an enteric polymer and a weakly basic drug: a strategy to enhance in vitro release

HT Nguyen, T Van Duong, LS Taylor - International Journal of …, 2023 - Elsevier
Recent work has highlighted that amorphous solid dispersions (ASDs) containing
delamanid (DLM) and an enteric polymer, hypromellose phthalate (HPMCP), appear to be …

The importance of surface composition and wettability on the dissolution performance of high drug loading amorphous dispersion formulations

TN Hiew, MA Solomos, P Kafle, H Polyzois… - Journal of …, 2025 - Elsevier
One of the limitations with an amorphous solid dispersion (ASD) formulation strategy is low
drug loading. Hydrophobic drugs have poor wettability and require a substantial amount of …

Surface Solid Dispersion of Ketoconazole on Trehalose Dihydrate using Spray Drying to Achieve Enhanced Dissolution Rate

W Weecharangsan, RJ Lee - AAPS PharmSciTech, 2024 - Springer
Ketoconazole (K) is a poorly water-soluble drug that faces significant challenges in
achieving therapeutic efficacy. This study aimed to enhance the dissolution rate of …

A Commentary on Co-Processed API as a Promising Approach to Improve Sustainability for the Pharmaceutical Industry

L Schenck, B Risteen, LM Johnson, A Koynov… - Journal of …, 2024 - Elsevier
Pharmaceutical products represent a meaningful target for sustainability improvement and
emissions reduction. It is proposed here that rethinking the standard, and often linear …

[HTML][HTML] Trends in amorphous solid dispersion drug products approved by the US Food and Drug Administration between 2012 and 2023

DE Moseson, TB Tran, B Karunakaran… - International Journal of …, 2024 - Elsevier
Abstract Forty-eight (48) drug products (DPs) containing amorphous solid dispersions
(ASDs) have been approved by the US Food and Drug Administration in the 12-year period …

Impact of route of particle engineering on dissolution performance of posaconazole

T **ang, Z Wang, M Solomos, S Axnanda… - International journal of …, 2025 - Elsevier
Even when they have similar particle size, micron sized drug crystals prepared via different
process routes may still exhibit considerable variability in pharmaceutical properties, due to …

Neat Amorphous Form and Amorphous Solid Dispersions of Apalutamide: A Comparative Study

R Sapkal, P Devangan, J Madan… - Journal of Drug Delivery …, 2025 - Elsevier
Amorphous form and Amorphous solid dispersions (ASDs) of an anticancer drug
Apalutamide (APA) with four polymers of different categories namely, PVPK30, HPMCAS …

Regulatory Considerations for Stability Studies of Co-Processed Active Pharmaceutical Ingredient

RK Orr, T Rawalpally, LS Gorka, LR Bonaga… - The AAPS Journal, 2024 - Springer
A co-processed active pharmaceutical ingredient (CP API) is the combination of an active
pharmaceutical ingredient (API) with non-active component (s). This technology has been …

Professor Lynne S. Taylor: Scientist, educator, and adventurer

DE Moseson, N Li, J Rantanen, K Ueda… - Journal of …, 2025 - Elsevier
This special edition of the Journal of Pharmaceutical Sciences is dedicated to Professor
Lynne S. Taylor (Retter Distinguished Professor of Pharmacy, Department of Industrial and …